[AXIATA] QoQ Cumulative Quarter Result on 30-Sep-2022 [#3]

Stock
[AXIATA] AXIATA GROUP BERHAD
Announcement Date
25-Nov-2022
Admission Sponsor
-
Sponsor
-
Financial Year
31-Dec-2022
Quarter
30-Sep-2022 [#3]
Profit Trend
QoQ- -35.09%
YoY- -128.7%
Quarter Report
Latest QR
Upcoming QR
AXIATA's Result
AXIATA's Financial Summary
View:
Show?
Cumulative Result
30/06/23 31/03/23 31/12/22 30/09/22 30/06/22 31/03/22 31/12/21 CAGR
Revenue 11,373,242 5,378,716 21,725,735 20,434,526 13,174,208 6,469,951 25,900,661 -42.31%
PBT -935,600 269,035 -4,248,292 808,553 539,969 253,220 2,173,618 -
Tax 355,717 -127,101 14,281,623 -837,576 -562,611 -262,511 -896,737 -
NP -579,883 141,934 10,033,331 -29,023 -22,642 -9,291 1,276,881 -
-
NP to SH -502,364 73,850 9,765,635 -201,755 -149,353 -42,974 818,900 -
-
Tax Rate - 47.24% - 103.59% 104.19% 103.67% 41.26% -
Total Cost 11,953,125 5,236,782 11,692,404 20,463,549 13,196,850 6,479,242 24,623,780 -38.31%
-
Net Worth 24,140,644 23,953,631 23,865,383 16,610,152 16,610,015 16,882,532 17,981,034 21.76%
Dividend
30/06/23 31/03/23 31/12/22 30/09/22 30/06/22 31/03/22 31/12/21 CAGR
Div 458,947 - 1,285,059 458,844 - - 871,529 -34.86%
Div Payout % 0.00% - 13.16% 0.00% - - 106.43% -
Equity
30/06/23 31/03/23 31/12/22 30/09/22 30/06/22 31/03/22 31/12/21 CAGR
Net Worth 24,140,644 23,953,631 23,865,383 16,610,152 16,610,015 16,882,532 17,981,034 21.76%
NOSH 9,178,951 9,178,951 9,179,084 9,177,028 9,176,804 9,176,804 9,174,986 0.02%
Ratio Analysis
30/06/23 31/03/23 31/12/22 30/09/22 30/06/22 31/03/22 31/12/21 CAGR
NP Margin -5.10% 2.64% 46.18% -0.14% -0.17% -0.14% 4.93% -
ROE -2.08% 0.31% 40.92% -1.21% -0.90% -0.25% 4.55% -
Per Share
30/06/23 31/03/23 31/12/22 30/09/22 30/06/22 31/03/22 31/12/21 CAGR
RPS 123.91 58.61 236.69 222.67 143.56 70.51 282.33 -42.33%
EPS -5.50 0.80 106.40 -2.20 -1.60 -0.50 8.90 -
DPS 5.00 0.00 14.00 5.00 0.00 0.00 9.50 -34.88%
NAPS 2.63 2.61 2.60 1.81 1.81 1.84 1.96 21.72%
Adjusted Per Share Value based on latest NOSH - 9,177,028
30/06/23 31/03/23 31/12/22 30/09/22 30/06/22 31/03/22 31/12/21 CAGR
RPS 123.85 58.57 236.59 222.53 143.47 70.46 282.06 -42.31%
EPS -5.47 0.80 106.35 -2.20 -1.63 -0.47 8.92 -
DPS 5.00 0.00 13.99 5.00 0.00 0.00 9.49 -34.84%
NAPS 2.6289 2.6085 2.5989 1.8088 1.8088 1.8385 1.9581 21.76%
Price Multiplier on Financial Quarter End Date
30/06/23 31/03/23 31/12/22 30/09/22 30/06/22 31/03/22 31/12/21 CAGR
Date 30/06/23 31/03/23 30/12/22 30/09/22 30/06/22 31/03/22 31/12/21 -
Price 2.65 3.01 3.09 2.62 2.83 3.79 4.16 -
P/RPS 2.14 5.14 1.31 1.18 1.97 5.37 1.47 28.53%
P/EPS -48.42 374.06 2.90 -119.17 -173.89 -809.19 46.60 -
EY -2.07 0.27 34.43 -0.84 -0.58 -0.12 2.15 -
DY 1.89 0.00 4.53 1.91 0.00 0.00 2.28 -11.78%
P/NAPS 1.01 1.15 1.19 1.45 1.56 2.06 2.12 -39.08%
Price Multiplier on Announcement Date
30/06/23 31/03/23 31/12/22 30/09/22 30/06/22 31/03/22 31/12/21 CAGR
Date 29/08/23 25/05/23 23/02/23 25/11/22 26/08/22 25/05/22 22/02/22 -
Price 2.57 2.96 3.15 3.03 3.03 3.19 3.92 -
P/RPS 2.07 5.05 1.33 1.36 2.11 4.52 1.39 30.50%
P/EPS -46.96 367.85 2.96 -137.82 -186.17 -681.09 43.92 -
EY -2.13 0.27 33.77 -0.73 -0.54 -0.15 2.28 -
DY 1.95 0.00 4.44 1.65 0.00 0.00 2.42 -13.44%
P/NAPS 0.98 1.13 1.21 1.67 1.67 1.73 2.00 -37.92%

PBT = Profit before Tax, NP = Net Profit, NP to SH = Net Profit Attributable to Shareholder, Div = Dividend, NP Margin = Net Profit Margin, ROE = Return on Equity, NOSH = Number of Shares, RPS = Revenue per Share, EPS = Earning Per Share, DPS = Dividend Per Share, NAPS = Net Asset Per Share, EOQ = End of Quarter, ANN = Announcement, P/RPS = Price/Revenue per Share, P/EPS = Price/Earning per Share, P/NAPS = Price/Net Asset per Share, EY = Earning Yield, DY = Dividend Yield.

NOSH is estimated based on the NP to SH and EPS. Div is an estimated figure based on the DPS and NOSH. Net Worth is an estimated figure based on the NAPS and NOSH.

Div Payout %, NP Margin, ROE, DY, QoQ ⃤ & YoY ⃤ figures in Percentage; RPS, EPS & DPS's figures in Cent; and NAPS's figures in Dollar.

All figures in '000 unless specified.

Discussions
Be the first to like this. Showing 0 of 0 comments
Post a Comment